变应原疫苗免疫治疗对过敏性支气管哮喘合并鼻炎的疗效分析  

Effect of allergen immunotherapy with standardized vaccine in patients with allergic asthma and rhinitis

作　　者：孙立英[1] 郭胤仕[1] 王菁兰[1] 王群[1] 王怡玮[1] 许以平[1] 

机构地区：[1]上海交通大学医学院附属仁济医院呼吸科/过敏性疾病诊治中心,200127

出　　处：《国际呼吸杂志》2011年第9期656-658,共3页International Journal of Respiration

摘　　要：目的评估标准化变应原疫苗免疫治疗（allergen immunotherapy，AIT）对过敏性哮喘合并鼻炎患者的近期疗效。方法设计调查问卷，对我院门诊接受标准化变应原疫苗安脱达（Alutard SQ）AIT治疗的39例过敏性哮喘合并鼻炎患者进行问卷调查，应用哮喘控制水平分级和哮喘控制测试（ACT）评分评价哮喘的疾病控制水平，应用鼻炎病情评分（RCT）评价过敏性鼻炎的控制情况。结果39例患者治疗前后的哮喘控制水平分级（Z=-7．235，P〈0．05）、ACT评分（t=16．533，P〈0．05）、RCT评分（t=16．650，P〈0．05）、情绪（x2=34．873，P〈0．05）等均有较大程度的改善。结论标准化AIT治疗能明显改善过敏性哮喘合并鼻炎患者的临床症状。Objective We sought to assess the effect of allergen immunotherapy （AIT） with Alutard SQ in patients with allergic asthma and rhinitis. Methods Designed the questionnaire and surveyed 39 patients with allergic asthma and rhinitis accepting AIT with Alutard SQ allergen extract so that we can know their situation before and after accepting AIT. We used levels of asthma control and Asthma Control Test（ACT）to evaluate their levels of asthma control, and used Rhinitis condition score （RCT） to evaluated their rhinitis control. Results 39 subjects completed the survey, and the results showed： AIT resulted in a significant improvement in levels of asthma control（ Z = -7. 235, P 〈0.05）, ACT（t =16.533, P 〈0.05）,RCT （t =16.650, P 〈0.05） and mood（x2 =34.873, P 〈0.05）. Conclusions AIT with Alutard~ SQ significantly improved symptoms of the patients with allergic asthma and rhinitis.

关 键 词：变应原疫苗免疫治疗 支气管哮喘 过敏性鼻炎 安脱达 问卷调查 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]